COVID-19 Policy Statement

Knowledge Center

Is it Worth the Risk?

As long as you know the risks and can bridge the gaps…

Whether you’re a superhero or a pharmaceutical manufacturer, risk is unavoidable. It can’t be ignored, but it can be managed. One of the biggest risks you face involves counterfeit medicines. They are a $200 billion annual business—that means they are the largest segment of fraudulent goods sold worldwide every year.

One of the major reasons for counterfeit medicines is the complexity of the pharmaceutical supply chain, which can have multiple tiers of suppliers and several geographic destinations. That’s why it is becoming increasing important to ensure the integrity of your pharmaceutical supply chain to close the gap on counterfeit medicines.

It’s true that effective, FDA-accepted technologies exist for both packaging and the pharmaceutical products themselves. But technology by itself is not enough. You also need a comprehensive risk assessment strategy to make the successful leap to prevention, early detection, and effective prosecution.

Proactively identifying which medicines are “at risk” of being counterfeited is the first step in understanding potential threats, and where the gaps are in your supply chain. First understand which of your high-value medicines are at risk, and then rank them according to their risk level. This will provide you the data needed to allocate the proper resources to eliminate those risks.

Authentix can help you manage counterfeit risks with our proven expertise and innovative authentication solutions. We’ve helped our customers mitigate risks to maximize revenues and build a competitive advantage.

Take our Risk Assessment Survey and find out which of your high-value drugs are at risk, and how we can help you protect them.

Download Blog PDF Here

COVID-19 Policy Statement


At Authentix, our mission to safeguard the integrity of global commerce is our priority as we continue to focus on customer needs with the challenges presented by the COVID-19 health emergency. Our corporate leadership team is monitoring the situation closely and its potential impact on supply chain continuity.

Our first and foremost commitment is to the health and safety of all Authentix employees. As we have said when faced with other similar infectious disease situations, we will never force Authentix employees to travel to geographic areas where they are uncomfortable or that present an increased risk of exposure to infectious disease.

Effective through April 30, 2020, we have closed the Addison Texas Facility to all personnel who do not require facility equipment to conduct their job, allowing for only those functions such as production/shipping/testing as needed to continue to serve our customers. We have banned all visitors to the Addison Texas Facility as well. We encourage all Authentix sites to enact a similar ban for employee safety and to restrict visitors, but realize this restriction is subject to local needs. We have further banned all air/train travel for all employees for Authentix business purposes. We ask that all customers, vendors or suppliers support these efforts and for those who present themselves at Authentix locations to respect and adhere to our policies and procedures that may limit access on this temporary basis.

We will continue to communicate regularly with our suppliers and updating contingency plans to ensure against any adverse impact or disruption to our customers, acknowledging that we are however subject to continued government restrictions and limited availability of transportation that may continue during this time. We encourage you to reach out to your Authentix point of contact with any questions or concerns.


Back To Top